Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 1997

View Archived Issues

Vical: Q3 1997 highlights

ICN: Q3 1997 highlights

Astra: Q3 and nine-month 1997 highlights

Spotlight on topoisomerase I inhibitors

P&U's Genotropin approved by FDA for adult growth hormone deficiency

FDA approves Intron A for non-Hodgkin's lymphoma

OP-1 exhibits protective effects against kidney damage

Dura submits NDA for Albuterol Spiros

ArQule, ViroPharma to collaborate on antiviral drugs

New neuroprotectants disclosed by Nippon Shinyaku

MDR-reversing agents reported by Nikken Chemicals

Radicicol derivatives with antitumor activity from Sankyo

Chugai discloses nitrovasodilators for angina, restenosis

Mitsui Toatsu reveals novel antitumor agents

Pola's newest antifungal agents disclosed in patent literature

Palatin obtains rights to new ED diagnostic/therapeutic

SKB to fund antiinfective research at Australian university

BioChem Pharma moves cell culture-based influenza vaccine to phase II/III

Preclinical profile of HMR's new KATP channel blocker

The selective PDE V inhibitor EMD-82639 shows potential in coronary insufficiency

New class of TNF-alpha inhibitors safe and well tolerated in phase I

C921-78: a new factor Xa antagonist prevents thrombosis with reduced blood loss

Potent and selective fibrinogen receptor antagonist presented by DuPont Merck

Nonpeptide alphav/beta3 antagonist effective in rabbit model of neointima formation

Tedisamil demonstrates favorable activity in patients with angina

New NHE inhibitor (EMD-85131) shows promise for ischemic heart disease

Amiodarone derivative may be suitable for long-term use

FDA review of Myotrophin continues after resubmission

PDE IV inhibitor from Almirall does not stimulate gastric acid secretion in rats

New guidelines for treating hypertension

Lerisetron: a potent, selective, long-acting and orally effective 5-HT3 antagonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...